title: Edaravone guards dopamine neurons in a rotenone model for Parkinson's disease.
abstract: 3-methyl-1-phenyl-2-pyrazolin-5-one (edaravone), an effective free radical scavenger, provides neuroprotection in stroke models and patients. In this study, we investigated its neuroprotective effects in a chronic rotenone rat model for Parkinson's disease. Here we showed that a five-week treatment with edaravone abolished rotenone's activity to induce catalepsy, damage mitochondria and degenerate dopamine neurons in the midbrain of rotenone-treated rats. This abolishment was attributable at least partly to edaravone's inhibition of rotenone-induced reactive oxygen species production or apoptotic promoter Bax expression and its up-regulation of the vesicular monoamine transporter 2 (VMAT2) expression. Collectively, edaravone may provide novel clinical therapeutics for PD.
authors.affiliation: Department of Neurology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Hubei, China.
authors.forename: Nian
authors.initials: N
authors.lastname: Xiong
authors.forename: Jing
authors.initials: J
authors.lastname: Xiong
authors.forename: Ghanshyam
authors.initials: G
authors.lastname: Khare
authors.forename: Chunnuan
authors.initials: C
authors.lastname: Chen
authors.forename: Jinsha
authors.initials: J
authors.lastname: Huang
authors.forename: Ying
authors.initials: Y
authors.lastname: Zhao
authors.forename: Zhentao
authors.initials: Z
authors.lastname: Zhang
authors.forename: Xian
authors.initials: X
authors.lastname: Qiao
authors.forename: Yuan
authors.initials: Y
authors.lastname: Feng
authors.forename: Harrish
authors.initials: H
authors.lastname: Reesaul
authors.forename: Yongxue
authors.initials: Y
authors.lastname: Zhang
authors.forename: Shenggang
authors.initials: S
authors.lastname: Sun
authors.forename: Zhicheng
authors.initials: Z
authors.lastname: Lin
authors.forename: Tao
authors.initials: T
authors.lastname: Wang
mesh_terms: D000818:Animals; D000983:Antipyrine / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000627:therapeutic use; D001522:Behavior, Animal / Q000187:drug effects; D004298:Dopamine / Q000378:metabolism*; D000077553:Edaravone; D016166:Free Radical Scavengers / Q000494:pharmacology / Q000627:therapeutic use*; D046352:Freezing Reaction, Cataleptic / Q000187:drug effects; D006801:Humans; D008297:Male; D009474:Neurons / Q000187:drug effects* / Q000502:physiology / Q000648:ultrastructure; D018696:Neuroprotective Agents / Q000494:pharmacology / Q000627:therapeutic use; D009483:Neuropsychological Tests; D020734:Parkinsonian Disorders / Q000139:chemically induced* / Q000188:drug therapy* / Q000473:pathology / Q000503:physiopathology; D051381:Rats; D017208:Rats, Wistar; D017382:Reactive Oxygen Species / Q000378:metabolism; D012402:Rotenone / Q000494:pharmacology*; D014475:Uncoupling Agents / Q000494:pharmacology; D050493:Vesicular Monoamine Transport Proteins / Q000235:genetics / Q000378:metabolism; D051028:bcl-2-Associated X Protein / Q000378:metabolism
chemical_list: D016166:Free Radical Scavengers; D018696:Neuroprotective Agents; D017382:Reactive Oxygen Species; C493454:Slc18a2 protein, rat; D014475:Uncoupling Agents; D050493:Vesicular Monoamine Transport Proteins; D051028:bcl-2-Associated X Protein; D012402:Rotenone; D000077553:Edaravone; D000983:Antipyrine; D004298:Dopamine